|Bid||25.22 x 4000|
|Ask||27.25 x 4000|
|Day's Range||26.85 - 27.50|
|52 Week Range||16.56 - 29.44|
|Beta (3Y Monthly)||0.97|
|PE Ratio (TTM)||76.92|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Horizon Therapeutics PLC (NASDAQ: HZNP ), an actively traded small-cap biotech, is poised for further upside in the near-term on its product strength, according to BMO Capital Markets. The Analyst Gary ...
Canada's patented drug price regulator, set to gain new powers next year, may be "more forgiving" in setting price caps for drugs that treat rare diseases, the agency's executive director told Reuters, as some advocates warned the country's pricing reforms would hurt patients. The Canadian government announced final regulations meant to cut drug spending on Friday. The reforms expand the Patented Medicine Prices Review Board's (PMPRB) powers, and among other things give it the ability to consider the cost-effectiveness of medications.
EVP, Corporate Affairs, CCO of Horizon Therapeutics Plc (30-Year Financial, Insider Trades) Geoffrey M. Continue reading...
Horizon Therapeutics stock popped Wednesday after its gout treatment, Krystexxa, drove a beat and raise in the second quarter. Adjusted Horizon earnings also came in better than expected.
Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 36.84% and 7.33%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
The best pharmaceutical stocks to buy have commonalities: strong Composite Ratings and Relative Strength Ratings.
Horizon Therapeutics (HZNP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors are always looking for growth in small-cap stocks like Horizon Therapeutics Public Limited Company...
Horizon Therapeutics (HZNP) is up 23.13%, and BioMarin (BMRN) is down 6.62% year-to-date. Let's study the drivers and risks for both these rare disease players in greater detail.
In this article we are going to estimate the intrinsic value of Horizon Therapeutics Public Limited Company...
Does Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) represent a good buying opportunity at the moment? Let’s quickly check the hedge fund interest towards the company. Hedge fund firms constantly search out bright intellectuals and highly-experienced employees and throw away millions of dollars on satellite photos and other research activities, so it is no wonder why […]
Horizon Therapeutics PLC NASDAQ/NGS:HZNPView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for HZNP with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding HZNP are favorable, with net inflows of $2.29 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
In 2008 Tim Walbert was appointed CEO of Horizon Therapeutics Public Limited Company (NASDAQ:HZNP). This report will...
Needless to say, this week got off to an ominous start for bulls, before Monday morning even rolled around. Despite a late rally on Friday that snapped a four-day losing streak in the U.S. markets, it still ended as the worst week in 2019 for the S&P 500. The CBOE Volatility Index (VIX) jumped 25% on Tuesday on top of a 20% gain on Monday, before declining 16% on Friday. When the dust settled, global markets had lost $1.451 trillion of value this week, according to Howard Silverblatt of S&P Dow Jones Indices.Selling pressure started over the weekend, when most investors probably weren’t even thinking about stocks. President Trump fired off a tweet last Sunday, suggesting the U.S. would raise tariffs on $200 billion of Chinese goods from 10% to 25% on Friday and consider taxing another $325 billion of items.A war of words ensued on both sides and the news kicked off a roller coaster ride in the global markets. The U.S. followed through with its threats on Friday and the Chinese have promised retaliatory trade actions. Looking AheadEarnings season officially ended this week, but several blue-chip names are still on the calendar to report quarterly results next week, highlighted by Cisco Systems (CSCO) on Wednesday and Wal-Mart (WMT) on Thursday.75% of companies in the S&P 500 exceeded profit estimates this quarter, which is above the historical average of 67%. The best growth was from the healthcare sector, while energy names were a drag on overall growth. Four weeks ago, aggregate earnings were expected to fall 3% to 4% year-over-year, but the actual results yielded a 1.2% increase.It appears that we managed to escape an earnings recession in the first quarter, but volatility has reared its ugly head again this week.After a hot start to the year, when the major U.S. stock market averages gained at least 14% through April, it’s scary to see how quickly those gains can evaporate. More than once this week, investors woke up to the news that the Dow Jones Industrial Average was set to open down 500 points or more.However, the fact remains that attractive investments are out there, if you’re willing to dig a little deeper. That’s where we come in.Because one such healthcare name that’s worth a closer look is our Stock of the Week below… Stock of the Week: Horizon Pharma (HZNP \- Research Report)Horizon was a breath of fresh air in a volatile week for investors. Management posted quarterly results on Wednesday that handily exceeded analyst expectations. Excluding one-time items, the company earned $0.30 a share in the first quarter. Revenue increased 25% from the previous year to $280 million and also came in ahead of expectations. We recently added HZNP to our Smart Investor portfolio and are pleased to see that shares soared 5.7% in the last week alone. Looking ahead, these gains should keep on coming. Here’s why: Treating Rare Diseases with Orphan DrugsThe company offers investors a little bit of everything, from growth at a reasonable price, to a pipeline bursting with opportunities in rheumatology and rare diseases.Horizon currently has 11 products on the market, led by Krystexxa, for uncontrollable gout. The company’s expertise is in rare diseases, where the majority of its revenue is generated. Management believes that Krystexxa can ultimately generate up to $750 million of annual sales in the U.S. and Horizon is currently seeking approval for two new indications, to increase the product’s addressable market. In late April, Horizon also said that Phase 3 studies for teprotumumab, its thyroid eye disease (TED) treatment, met primary and secondary endpoints. Management plans to file a Biologics License Application with the U.S. Food and Drug Administration (FDA) later this year. TED affects 15k-20k patients each year in the U.S. and there are no existing FDA-approved treatments. Teprotumumab has already been designated an orphan drug, with fast-track and breakthrough therapy status. The company estimates the product could also generate $750 million of peak annual revenue in the U.S. Analysts See Continued UpsideEarlier this month, Liav Abraham of Citigroup upgraded the stock from Neutral to Buy. Seven of nine active analysts now rate Horizon a Buy and the average price target of $32.22 suggests 14.8% upside from current levels.“Post a 1Q19 beat, we are reiterating our OW rating and 12- month PT of $32. We continue to expect upside to FactSet estimates for HZNP's orphan as well as rheumatology businesses and multiple expansion to drive the stock higher” wrote top-ranked Cantor Fitzgerald analyst Louise Chen recently. View HZNP Price Target & Analyst Ratings DetailThe analyst community calls for the company to deliver 18.1% compound earnings growth over the next two years. In the meantime, Horizon trades at just 16x expected 2019 earnings of $1.75 a share, which suggests that its price has room to grow. Management is using these profits to improve the balance sheet. Coupled with proceeds from an equity offering in March, the company plans to pay down $550 million of debt this year.Finally, I’m encouraged to note the stock sports a Smart Score of 10/10 on TipRanks, suggesting the potential for continued price momentum. This new proprietary metric utilizes Big Data to rank stocks based on 8 key factors that have historically been a precursor to future outperformance.View HZNP Smart Score DetailIn addition to the catalysts mentioned above, Smart Score notes that Horizon has positive technical momentum and sentiment from bloggers and investors.FYI: This is just 1 of the 20+ stocks selected for the Smart Investor portfolio. That’s where we share more detailed insights on our weekly stock picks. You may also want to learn more about how we use TipRanks indicators to find stocks that are primed to outperform. Discover the Smart Investor portfolio here >> Wishing you a world of investment success!
Horizon Therapeutics' (HZNP) sales beat estimates in the first quarter of 2019, primarily owing to strong performance of Krystexxa, Ravicti, Procysbi and Rayos.
Horizon Therapeutics stock edged closer to a breakout Wednesday after the pharmaceutical company topped first-quarter expectations, though a key gout treatment lagged Street forecasts.